Acellular pertussis vaccine efficacy: An updated systematic review and meta -analysis

Roxana Mansour-Ghanaei1, Maziar Moradi-Lakeh2, Sareh Shakerian3

  • 1MD, Pediatric Infectious Specialist, Pediatric Infections Research Center, Mofid children Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran. roxanaghanaie@yahoo.com.

Insights

The acellular pertussis vaccine demonstrates superior efficacy and safety compared to the whole cell vaccine in children. It also shows acceptable effectiveness in high-risk adults, supporting its introduction into national immunization programs.

Area of Science:

  • Immunology
  • Vaccinology
  • Public Health

Background:

  • Rising incidence of pertussis (whooping cough) globally necessitates updated vaccination strategies.
  • Current Expanded Program on Immunization (EPI) in Iran uses whole cell pertussis vaccines.
  • Need to evaluate acellular pertussis vaccines for children and high-risk adults.

Purpose of the Study:

  • To systematically review and meta-analyze the efficacy of acellular pertussis vaccines in children and high-risk adults.
  • To compare the effectiveness of acellular vaccines against whole cell vaccines and placebo.
  • To provide evidence for the potential introduction of acellular vaccines into Iran's national immunization program.

Main Methods:

  • Systematic literature review focusing on previously published systematic reviews.
  • Methodological quality assessment using the AMSTAR tool.
  • Updated evidence search until February 2014, followed by meta-analysis using Stata.

Main Results:

  • Acellular vs. whole cell vaccine efficacy in children: pooled estimate 0.68 (95% CI, 0.55-0.81).
  • Acellular vs. placebo efficacy in children: pooled estimate 0.70 (95% CI, 0.60-0.80).
  • Acellular booster dose efficacy vs. placebo: pooled estimate 0.87 (95% CI, 0.85-0.88).
  • Acellular vaccine efficacy in high-risk adults: pooled estimate 0.78 (95% CI, 0.64-0.93).

Conclusions:

  • Acellular pertussis vaccines exhibit superior performance and safety over whole cell vaccines in children.
  • The acellular vaccine demonstrates acceptable efficacy for high-risk adult populations.
  • Evidence supports the integration of acellular pertussis vaccines into national immunization schedules.